Successful, we will reply to you quickly.OK
Please select the quantity.OK
Your message is being sent, please wait.Close
Send mail failed, please send again!Close
Products are for research use only. Not for human use. We do not sell to patients.
INK-128 Chemical Structure
|Product name: INK-128|
|Cat. No.: HY-13328|
INK 128 is a potent and selective mTOR inhibitor with IC50 of 1 nM; >200-fold less potent to class I PI3K isoforms.
IC50 value: 1 nM 
in vitro: INK 128 exhibits an enzymatic inhibition activity against mTOR and more than 100-fold selectivity to PI3K kinases . As TORC1/2 inhibitor, INK 128 inhibits both the phosphorylation of S6 and 4EBP1, the downstream substrates of TORC1, and selectively inhibits AKT phosphorylation at Ser473, the downstream substrate of TORC2. Furthermore, INK 128 also shows potent inhibition effects on cell lines resistant to rapamycin and pan-PI3K inhibitors .
in vivo: In a ZR-75-1 breast cancer xenograft model, INK 128 shows tumor growth inhibition efficacy at a dose of 0.3 mg/kg/day.  Daily, oral administration of INK 128 inhibits angiogenesis and tumor growth in multiplexenograft models .
|M.Wt||309.33||Storage||Please store the product under the recommended conditions in the Certificate of Analysis.|
|Solvent & Solubility||
10 mM in DMSO
|1 mg||5 mg||10 mg|
|1 mM||3.2328 mL||16.1640 mL||32.3279 mL|
|5 mM||0.6466 mL||3.2328 mL||6.4656 mL|
|10 mM||0.3233 mL||1.6164 mL||3.2328 mL|
|Product Name||Sponsor Only||Condition||Start Date||End Date||Phase||Last Change Date|
|INK-128||Millennium Pharmaceuticals Inc||Non-Hodgkin lymphoma||30-NOV-10||31-JAN-14||Phase 1||05-AUG-13|
|Millennium Pharmaceuticals Inc||Macroglobulinemia||30-NOV-10||31-JAN-14||Phase 1||05-AUG-13|
|Millennium Pharmaceuticals Inc||Advanced solid tumor||31-JUL-13||30-NOV-16||Phase 1||12-SEP-13|
|Millennium Pharmaceuticals Inc||Advanced solid tumor||31-JAN-10||31-MAR-15||Phase 1||25-JUL-13|
|Millennium Pharmaceuticals Inc||Advanced solid tumor||31-MAR-11||28-FEB-14||Phase 1||20-NOV-13|
|Millennium Pharmaceuticals Inc||Multiple myeloma||30-NOV-10||31-JAN-14||Phase 1||05-AUG-13|
3-Methyladenine (3-MA) is a selective PI3K inhibitor for Vps34 and PI3K(gamma) with IC50 of 25 (mu)M and 60 (mu)M.
A66 is a potent and specific p110(alpha) inhibitor with IC50 of 32 nM, >100 fold selectivity for p110(alpha) over other class-I PI3K isoforms.
Acalisib (GS-9820) is a potent and selective inhibitor of PI3K(delta) with IC50 value of 12.7 nM.
AMG319 is a potent and selective PI3K(delta) inhibitor with IC50 of 18 nM, also inhibits PI3K(gamma) with IC50 of 850 nM.
AP1903 is a homodimer binding to FKBP; elicites potent and dosedependent apoptotic death of engineered cell line HT1080 in culture with an EC50 of 0.1 nM
AP20187 is a synthetic, cell-permeable ligand that can be used to induce homodimerization of fusion proteins containing the DmrB domain.
AS-252424 is a potent and selective inhibitor of PI3K(gamma) with IC50 of 33 nM; >10 fold selectivity for PI3K(gamma) versus PI3K(alpha).
AS-605240 is a potent and selective inhibitor of PI 3-kinase (gamma) (PI3K(gamma)) (IC50 = 8 nM). AS-605240 displays 30-fold selectivity over PI3K(delta) and PI3K(beta) and 7.5-fold selectivity over PI3K(alpha).
AZD6482 is a PI3K(beta) inhibitor with IC50 of 10 nM, 8-, 87- and 109-fold more selective to PI3K(beta) than PI3K(delta), PI3K(alpha) and PI3K(gamma).
AZD8055 is a novel ATP-competitive mTOR inhibitor with IC50 of 0.8 nM with excellent selectivity (～1,000-fold) against PI3K isoforms and ATM/DNA-PK.
Other Countries & RegionsSee Worldwide Distributors